Initial List Of US Essential Medicines Focuses On Acute Care
Executive Summary
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
You may also be interested in...
Perrigo’s Loss Is Lupin’s Gain On Albuterol
Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.
Perrigo’s Loss Is Lupin’s Gain
Having gained from Perrigo’s withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by Q4 as demand is seen rising on account of flu and COVID-29 cases in the US. Meanwhile, FDA observations at its Somerset facility are a dampener
New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: